Taylor B K, Peterson M A, Basbaum A I
Department of Anatomy, University of California San Francisco, 94143-0452, USA.
J Pharmacol Exp Ther. 1997 Feb;280(2):876-83.
Injection of dilute formalin into the hindpaw produces brief (phase 1) and persistent (phase 2) nociceptive responses in the rat. We recently reported that ongoing peripheral nerve input is required for the expression of behavioral and cardiovascular responses during phase 2. Here we evaluated the contribution of central and peripheral sensitization mechanisms, generated during phase 1, to the magnitude and temporal profile of phase 2. During phase 1, we administered analgesic doses of an ultrashort-acting opioid, remifentanil (i.v. administration from 0-5 min after 5.0% formalin injection), or anesthetic concentrations of halothane (2.1%). Inhibition of phase 1 did not reduce the magnitude of flinching and cardiovascular responses during phase 2, but it did delay their onset and/or termination. Longer remifentanil infusions (0-15 or 0-30 min) produced even longer delays (up to 30 min) in the onset and termination of flinching during phase 2; however, when remifentanil was administered during the early part of phase 2 (15-30 or 15-45 min), it did not prolong the time to termination of phase 2. Continuous infusion (10 mg/kg/hr i.v.) of a peripherally acting opiate antagonist, naloxone methiodide, did not reduce the antinociception produced by remifentanil during phase 1 but almost completely reversed the delay in the onset and termination of phase 2. We conclude that central sensitization mechanisms during phase 1 do not influence the magnitude of phase 2. We also hypothesize that remifentanil interacts with peripheral opioid receptors to impede the formalin-evoked synthesis and/or release of proinflammatory compounds during phase 1 and thus delay phase 2.
将稀释的福尔马林注射到大鼠后爪会产生短暂的(第1阶段)和持续的(第2阶段)伤害性反应。我们最近报道,在第2阶段期间,正在进行的外周神经输入是行为和心血管反应表达所必需的。在此,我们评估了在第1阶段产生的中枢和外周敏化机制对第2阶段的幅度和时间进程的贡献。在第1阶段,我们给予超短效阿片类药物瑞芬太尼的镇痛剂量(在5.0%福尔马林注射后0至5分钟静脉注射),或氟烷的麻醉浓度(2.1%)。对第1阶段的抑制并没有降低第2阶段退缩和心血管反应的幅度,但确实延迟了它们的开始和/或终止。更长时间的瑞芬太尼输注(0至15或0至30分钟)在第2阶段退缩的开始和终止方面产生了更长时间的延迟(长达30分钟);然而,当在第2阶段早期(15至30或15至45分钟)给予瑞芬太尼时,它并没有延长第2阶段终止的时间。外周作用的阿片类拮抗剂甲硫氨酸纳洛酮的持续输注(10毫克/千克/小时静脉注射)在第1阶段并没有降低瑞芬太尼产生的抗伤害感受,但几乎完全逆转了第2阶段开始和终止的延迟。我们得出结论,第1阶段的中枢敏化机制不会影响第2阶段的幅度。我们还假设,瑞芬太尼与外周阿片受体相互作用,在第1阶段阻碍福尔马林诱发的促炎化合物的合成和/或释放,从而延迟第2阶段。